PHATHOM PHARMACEUTICALS, INC. Operating Income
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Operating Income of -$3.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$3.96M.
- PHATHOM PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$15.48M.
- PHATHOM PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$5.93M.
- PHATHOM PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$15.27M.
- PHATHOM PHARMACEUTICALS, INC. operating income (loss) for fiscal 2025 was -$159.99M.
- PHATHOM PHARMACEUTICALS, INC. operating income (loss) for fiscal 2024 was -$277.47M.
- PHATHOM PHARMACEUTICALS, INC. operating income (loss) for fiscal 2023 was -$167.31M.
- PHATHOM PHARMACEUTICALS, INC. operating income (loss) for fiscal 2022 was -$172.44M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$3.96M 10-Q · filed 2026-07-30 | -$19.44M 10-Q · filed 2026-07-30 | -$25.37M derived: sum of 3 quarters · filed 2026-07-30 | -$40.64M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | -$15.48M 10-Q · filed 2026-04-30 | -$21.41M derived: sum of 2 quarters · filed 2026-04-30 | -$36.68M derived: sum of 3 quarters · filed 2026-04-30 | -$96.60M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | -$5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$21.20M derived: sum of 2 quarters · filed 2026-02-26 | -$81.12M derived: sum of 3 quarters · filed 2026-07-30 | -$159.99M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$15.27M 10-Q · filed 2025-10-30 | -$75.19M derived: sum of 2 quarters · filed 2026-07-30 | -$154.06M 10-Q · filed 2025-10-30 | -$213.47M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$59.92M 10-Q · filed 2026-07-30 | -$138.79M 10-Q · filed 2026-07-30 | -$198.20M derived: sum of 3 quarters · filed 2026-07-30 | -$269.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | -$78.86M 10-Q · filed 2026-04-30 | -$138.28M derived: sum of 2 quarters · filed 2026-04-30 | -$209.08M derived: sum of 3 quarters · filed 2026-04-30 | -$286.38M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | -$59.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$130.21M derived: sum of 2 quarters · filed 2026-02-26 | -$207.51M derived: sum of 3 quarters · filed 2026-02-26 | -$277.47M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$70.80M 10-Q · filed 2025-10-30 | -$148.10M derived: sum of 2 quarters · filed 2025-10-30 | -$218.05M 10-Q · filed 2025-10-30 | -$287.93M derived: sum of 4 quarters · filed 2025-10-30 | |
| 2024-06-30 | -$77.30M 10-Q · filed 2025-08-07 | -$147.25M 10-Q · filed 2025-08-07 | -$217.13M derived: sum of 3 quarters · filed 2025-08-07 | -$252.79M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$69.95M 10-Q · filed 2025-05-01 | -$139.83M derived: sum of 2 quarters · filed 2025-05-01 | -$175.49M derived: sum of 3 quarters · filed 2025-05-01 | -$207.19M derived: sum of 4 quarters · filed 2025-05-01 | |
| 2023-12-31 | -$69.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$105.53M derived: sum of 2 quarters · filed 2025-03-06 | -$137.24M derived: sum of 3 quarters · filed 2025-03-06 | -$167.31M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$35.66M 10-Q · filed 2024-11-07 | -$67.36M derived: sum of 2 quarters · filed 2024-11-07 | -$97.44M 10-Q · filed 2024-11-07 | -$144.08M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$31.70M 10-Q · filed 2024-08-08 | -$61.78M 10-Q · filed 2024-08-08 | -$108.42M derived: sum of 3 quarters · filed 2024-08-08 | -$150.95M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$30.08M 10-Q/A · filed 2024-06-14 | -$76.72M derived: sum of 2 quarters · filed 2024-06-14 | -$119.25M derived: sum of 3 quarters · filed 2024-06-14 | -$164.61M derived: sum of 4 quarters · filed 2024-06-14 | |
| 2022-12-31 | -$46.64M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | -$89.17M derived: sum of 2 quarters · filed 2024-06-14 | -$134.53M derived: sum of 3 quarters · filed 2024-06-14 | -$172.44M 10-K/A · filed 2024-06-14 | |
| 2022-09-30 | -$42.53M 10-Q · filed 2023-11-09 | -$87.89M derived: sum of 2 quarters · filed 2023-11-09 | -$125.80M 10-Q · filed 2023-11-09 | -$158.84M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$45.36M 10-Q · filed 2023-08-10 | -$83.27M 10-Q · filed 2023-08-10 | -$83.27M 10-Q · filed 2022-08-02 | -$116.31M derived: sum of 3 quarters · filed 2023-08-10 | -$149.45M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$37.91M 10-Q · filed 2023-05-10 | -$70.95M derived: sum of 2 quarters · filed 2023-05-10 | -$104.08M derived: sum of 3 quarters · filed 2023-05-10 | -$139.40M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | -$33.04M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | -$66.18M derived: sum of 2 quarters · filed 2023-02-28 | -$101.50M derived: sum of 3 quarters · filed 2023-02-28 | -$135.08M 10-K · filed 2023-02-28 | |
| 2021-09-30 | -$33.14M 10-Q/A · filed 2022-11-09 | -$68.46M derived: sum of 2 quarters · filed 2022-11-09 | -$102.04M 10-Q/A · filed 2022-11-09 | -$154.48M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | -$35.32M 10-Q · filed 2022-08-02 | -$68.90M 10-Q · filed 2022-08-02 | -$121.34M derived: sum of 3 quarters · filed 2022-08-02 | -$154.17M derived: sum of 4 quarters · filed 2022-08-02 | |
| 2021-03-31 | -$33.58M 10-Q · filed 2022-05-10 | -$86.02M derived: sum of 2 quarters · filed 2022-05-10 | -$118.85M derived: sum of 3 quarters · filed 2022-05-10 | -$138.87M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$52.44M 10-K · filed 2021-03-30 | -$85.27M derived: sum of 2 quarters · filed 2021-11-08 | -$105.29M derived: sum of 3 quarters · filed 2021-11-08 | -$125.67M 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$32.83M 10-Q · filed 2021-11-08 | -$52.85M derived: sum of 2 quarters · filed 2021-11-08 | -$73.23M 10-Q · filed 2021-11-08 | -$88.92M derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-06-30 | -$20.02M 10-Q · filed 2021-08-10 | -$40.40M 10-Q · filed 2021-08-10 | -$56.09M derived: sum of 3 quarters · filed 2021-08-10 | -$62.37M derived: sum of 4 quarters · filed 2021-08-10 | |
| 2020-03-31 | -$20.38M 10-Q · filed 2021-05-11 | -$36.07M derived: sum of 2 quarters · filed 2021-05-11 | -$42.35M derived: sum of 3 quarters · filed 2021-05-11 | -$125.36M derived: sum of 4 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$15.69M 10-K · filed 2021-03-30 | -$21.98M derived: sum of 2 quarters · filed 2021-03-30 | -$104.99M derived: sum of 3 quarters · filed 2021-03-30 | -$106.22M 10-K · filed 2021-03-30 | |
| 2019-09-30 | -$6.28M 10-K · filed 2021-03-30 | -$89.30M derived: sum of 2 quarters · filed 2021-03-30 | -$90.52M 10-Q · filed 2020-11-10 | -$90.97M derived: sum of 4 quarters · filed 2021-03-30 | |
| 2019-06-30 | -$83.01M 10-K · filed 2021-03-30 | -$84.24M 10-Q · filed 2020-08-06 | -$84.69M derived: sum of 3 quarters · filed 2021-03-30 | -$84.96M derived: sum of 4 quarters · filed 2021-03-30 | |
| 2019-03-31 | -$1.23M 10-K · filed 2021-03-30 | -$1.68M derived: sum of 2 quarters · filed 2021-03-30 | -$1.95M derived: sum of 3 quarters · filed 2021-03-30 | -$2.20M derived: sum of 4 quarters · filed 2021-03-30 | |
| 2018-12-31 | -$451.00K 10-K · filed 2020-03-19 | -$719.00K derived: sum of 2 quarters · filed 2020-03-19 | -$974.00K derived: sum of 3 quarters · filed 2020-03-19 | -$1.23M 10-K · filed 2020-03-19 | |
| 2018-09-30 | -$268.00K 10-K · filed 2020-03-19 | -$523.00K derived: sum of 2 quarters · filed 2020-03-19 | -$774.00K 10-Q · filed 2019-11-25 | ||
| 2018-06-30 | -$255.00K 10-K · filed 2020-03-19 | -$506.00K derived: sum of 2 quarters · filed 2020-03-19 | |||
| 2018-03-31 | -$251.00K 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |